Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Suspended 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell 1Lymphoma, Large-Cell, Anaplastic 1Immunoblastic Lymphadenopathy 1

Interventions

Bortezomib 9Cyclophosphamide 7tanespimycin 4fludarabine phosphate 4Vorinostat 4Paclitaxel 4Filgrastim 4Carboplatin 4fludarabine 3Peripheral Blood Stem Cell Transplantation 3Lenalidomide 3Irinotecan 3Everolimus 3Etoposide 3Doxorubicin 3Dasatinib 3Azacitidine 3sargramostim 2romidepsin 2laromustine 2ixabepilone 2entinostat 2belinostat 2Whole-Body Irradiation 2Vincristine 2Topotecan 2Tacrolimus 2Radiotherapy 2Prednisone 2Pharmacogenomic Testing 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Immunoblastic Lymphadenopathy × Abatacept × Clear all
NCT07388563 2026-05-08

Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma

National Institutes of Health Clinical Center (CC)

Phase 1 Suspended
20 enrolled
LymphoidOther hematologic neoplasm

Immunoblastic Lymphadenopathy, Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡